Clinical Trial Update: Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing safety of a single 2 g oral dose of Solosec (secnidazole) for adolescent girls with bacterial vaginosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Vaginosis

Drugs mentioned

• SOLOSEC (secnidazole)

Snippet

Sponsor: Lupin Research Inc | Conditions: Bacterial Vaginoses | Phase 4 | Status: COMPLETED